Skip to main content

EHR Reminders, Outreach Improve Follow-Up for Abnormal Cancer Screening

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Oct. 13, 2023 -- A multilevel primary care intervention including electronic health record (EHR) reminders and patient outreach improves timely follow-up of overdue cancer screening test results, according to a study published in the Oct. 10 issue of the Journal of the American Medical Association.

Steven J. Atlas, M.D., M.P.H., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues conducted a cluster randomized clinical trial at 44 primary care practices within three health networks enrolling patients with at least one abnormal cancer screening test result. Follow-up actions and times for abnormal screening results were recommended using automated algorithms developed using data from electronic health records. Primary care practices were randomly assigned to usual care; EHR reminders; EHR reminders and outreach; or EHR reminders, outreach, and navigation.

A total of 11,980 patients with an abnormal cancer screening test result for colorectal cancer, cervical cancer, breast cancer, or lung cancer (69, 22, 8, and 1 percent, respectively) and abnormal test results categorized as low, medium, or high risk (51, 31, and 18 percent, respectively) were included. The researchers found that 31.4, 31.0, 22.7, and 22.9 percent of patients in the EHR reminders, outreach, and navigation group; EHR reminders and outreach group; EHR reminders group; and usual care group completed recommended follow-up within 120 days, respectively. Similar results were seen for completion of recommended follow-up within 240 days and by subgroups for cancer type and level of risk for the abnormal screening result.

"Compared with patients treated at practices randomized to usual care or passive EHR reminders, completion of follow-up within 120 days of enrollment was higher among patients in practices randomized to EHR reminders and outreach (via letters and phone calls with or without patient navigation)," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Vaginal Cancer Incidence Increasing Globally

WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.